Antiemetic Gains Pediatric Indication for Chemo-induced Nausea, Vomiting

Share this content:
Antiemetic Gains Pediatric Indication for Chemo-induced Nausea, Vomiting
Antiemetic Gains Pediatric Indication for Chemo-induced Nausea, Vomiting

Eisai and the Helsinn Group announced that the FDA has approved Aloxi (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy, in children aged 1 month to <17 years. This marks the first approved drug for acute chemotherapy-induced nausea and vomiting (CINV) prevention in patients aged 1–6 months.

RELATED: Side-Effect Management

Four pediatric clinical trials were conducted to assess Aloxi as requested by the FDA. The approval was based on a randomized, double-blind, non-inferiority trial comparing single-dose Aloxi 20mcg/kg IV given 30 minutes prior to chemotherapy vs. ondansetron 0.15mg/kg IV (standard of care) given 30 minutes prior to chemotherapy followed by infusions 4 and 8 hours after the first dose of ondansetron. Within the first 24 hours after chemotherapy, Complete Response (defined as no vomiting, no retching and no antiemetic rescue medication) was achieved in 59.4% of patients who received Aloxi vs. 58.6% of those who received the ondansetron regimen.

RELATED: Antiemetic Medications

Aloxi, a selective 5-HT3 receptor antagonist, is already approved for use in adults to help prevent acute or delayed nausea and vomiting due to initial and repeat courses of certain chemotherapy.

For more information call (888) 274-2378 or visit Aloxi.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs